Tetralogic Pharmaceuticals Corp (TLOG) 4.31 $TLOG
Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 43.44 (-1.22), ENZN: 1.72 (+0.18), CDZI: 8.76 (-0.06), BNSO: 1.69 (+0.09), DTLK: 11.99 (+0.07), NYMX: 1.39 (-0.05), IDSY: 7.09 (+0.07), VLTC: 11.54 (+0.50), TLOG: 4.31 (-0.51), UCTT: 6.26 (+0.60), OBAS: 7.20 (unch)
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
GlobeNewswire - Tue Apr 21, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that research describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus (HBV) has been published in the journal Proceedings of the National Academy of Sciences.
TLOG: 4.31 (-0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Merck and TetraLogic Pharma establish clinical study collaboration
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:00AM CDT
MRK: 57.60 (+0.09), TLOG: 4.31 (-0.51)
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
GlobeNewswire - Mon Apr 20, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015.
MRK: 57.60 (+0.09), TLOG: 4.31 (-0.51)
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 9:11AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York. Mr. Buchi will provide an overview of the Company and its corporate activities.
TLOG: 4.31 (-0.51)
TetraLogic beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:49PM CST
TLOG: 4.31 (-0.51)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EOPN: 8.59 (unch), HPJ: 4.33 (+0.09), GLUU: 5.45 (+0.09), BPFH: 13.06 (+0.03), TLOG: 4.31 (-0.51), SOFO: 9.92 (-0.09), EGLT: 10.26 (+0.05), BBSI: 40.79 (-1.06), SLAB: 50.89 (-1.75), CONN: 30.85 (+0.15), CBMG: 29.51 (-1.85), ALQA: 4.96 (+0.16), LWAY: 20.28 (-0.31)
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
GlobeNewswire - Thu Dec 18, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T-cell lymphoma ("CTCL"
.
TLOG: 4.31 (-0.51)
Market Maker Surveillance Report. JRJC, ECSL, TLOG, WLDN, HGSH, EKSO, Losing Stocks With Lowest Price Friction For Tuesday, December 16th 2014
M2 - Wed Dec 17, 2:18AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5122 companies with "abnormal" market making, 2762 companies with positive Friction Factors and 4010 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Finance Online Co Ltd (NASDAQ:JRJC), ECARE SOLUTIONS INC (OTC:ECSL), TRANSFORM LOGIC CORP (NASDAQ:TLOG), Willdan Group Inc (NASDAQ:WLDN), China Hgs Real Estate Inc (NASDAQ:HGSH), (OTC:EKSO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
JRJC: 5.59 (+0.08), HGSH: 3.28 (+0.05), TLOG: 4.31 (-0.51), WLDN: 15.87 (-0.30)
TetraLogic Provides Update on Ovarian Cancer Study
GlobeNewswire - Tue Dec 16, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles).
AMGN: 167.91 (-1.26), TLOG: 4.31 (-0.51)
TetraLogic Pharma perking up
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 9:23AM CST
TLOG: 4.31 (-0.51)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Thu Dec 04, 6:29AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56 Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.
TLOG: 4.31 (-0.51)
TetraLogic to Participate in Two Conferences in December
GlobeNewswire - Tue Dec 02, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York this month:
TLOG: 4.31 (-0.51)
Andrew L. Pecora of TetraLogic Pharmaceuticals Corporation (TLOG)-NasdaqGM bought Shares of TLOG
M2 - Thu Nov 20, 7:06AM CST
Reported by InsiderCow.com at 2014-11-19 12:36:34 ET
TLOG: 4.31 (-0.51)
TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
GlobeNewswire - Mon Nov 10, 7:42AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.
TLOG: 4.31 (-0.51)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 43.44 (-1.22), ENZN: 1.72 (+0.18), CDZI: 8.76 (-0.06), BNSO: 1.69 (+0.09), DTLK: 11.99 (+0.07), NYMX: 1.39 (-0.05), IDSY: 7.09 (+0.07), VLTC: 11.54 (+0.50), TLOG: 4.31 (-0.51), UCTT: 6.26 (+0.60), OBAS: 7.20 (unch)
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
GlobeNewswire - Tue Apr 21, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that research describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus (HBV) has been published in the journal Proceedings of the National Academy of Sciences.
TLOG: 4.31 (-0.51)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Merck and TetraLogic Pharma establish clinical study collaboration
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:00AM CDT
MRK: 57.60 (+0.09), TLOG: 4.31 (-0.51)
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
GlobeNewswire - Mon Apr 20, 7:00AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015.
MRK: 57.60 (+0.09), TLOG: 4.31 (-0.51)
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 9:11AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. Eastern Time at the Westin Grand Central Hotel in New York. Mr. Buchi will provide an overview of the Company and its corporate activities.
TLOG: 4.31 (-0.51)
TetraLogic beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:49PM CST
TLOG: 4.31 (-0.51)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EOPN: 8.59 (unch), HPJ: 4.33 (+0.09), GLUU: 5.45 (+0.09), BPFH: 13.06 (+0.03), TLOG: 4.31 (-0.51), SOFO: 9.92 (-0.09), EGLT: 10.26 (+0.05), BBSI: 40.79 (-1.06), SLAB: 50.89 (-1.75), CONN: 30.85 (+0.15), CBMG: 29.51 (-1.85), ALQA: 4.96 (+0.16), LWAY: 20.28 (-0.31)
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
GlobeNewswire - Thu Dec 18, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T-cell lymphoma ("CTCL"
. TLOG: 4.31 (-0.51)
Market Maker Surveillance Report. JRJC, ECSL, TLOG, WLDN, HGSH, EKSO, Losing Stocks With Lowest Price Friction For Tuesday, December 16th 2014
M2 - Wed Dec 17, 2:18AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5122 companies with "abnormal" market making, 2762 companies with positive Friction Factors and 4010 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Finance Online Co Ltd (NASDAQ:JRJC), ECARE SOLUTIONS INC (OTC:ECSL), TRANSFORM LOGIC CORP (NASDAQ:TLOG), Willdan Group Inc (NASDAQ:WLDN), China Hgs Real Estate Inc (NASDAQ:HGSH), (OTC:EKSO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
JRJC: 5.59 (+0.08), HGSH: 3.28 (+0.05), TLOG: 4.31 (-0.51), WLDN: 15.87 (-0.30)
TetraLogic Provides Update on Ovarian Cancer Study
GlobeNewswire - Tue Dec 16, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles).
AMGN: 167.91 (-1.26), TLOG: 4.31 (-0.51)
TetraLogic Pharma perking up
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 9:23AM CST
TLOG: 4.31 (-0.51)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Thu Dec 04, 6:29AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56 Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.
TLOG: 4.31 (-0.51)
TetraLogic to Participate in Two Conferences in December
GlobeNewswire - Tue Dec 02, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York this month:
TLOG: 4.31 (-0.51)
Andrew L. Pecora of TetraLogic Pharmaceuticals Corporation (TLOG)-NasdaqGM bought Shares of TLOG
M2 - Thu Nov 20, 7:06AM CST
Reported by InsiderCow.com at 2014-11-19 12:36:34 ET
TLOG: 4.31 (-0.51)
TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
GlobeNewswire - Mon Nov 10, 7:42AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.
TLOG: 4.31 (-0.51)
